acute myeloid leukemia (AML) | Page 35 | Aplastic Anemia & MDS International Foundation Return to top.

acute myeloid leukemia (AML)

Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Achieved Outcomes Comparable With Matched Unrelated Donor Transplantation in Young Acquired Severe Aplastic Anemia

Author(s): 
Lu Y, Sun RJ, Zhao YL, Xiong M, Cao XY, Zhang JP, Wei ZJ, Zhou JR, Liu DY, Lu DP
Primary Author: 
Lu Y
Journal Title: 
Biol Blood Marrow Transplant
Original Publication Date: 
May 2018

Salvage haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is considered in patients with severe

Bone Marrow Disease(s): 

Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Author(s): 
Slade M, DiPersio J, Westervelt P, Vij R, Schroeder M, Romee R
Primary Author: 
Slade M
Journal Title: 
Biology of Blood and Marrow Transplantation
Original Publication Date: 
Nov 2017

Many hematologic malignancies are diseases of aging, and the use of hematopoietic cell transplant (HCT) is growing rapidly among older adults. Modern post-transplant

Orlando

Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.

Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.
Event Date: 
Sat, 11/04/2017 - 8:00am (EDT)
Conference Event Type: 

Kansas City

Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.

Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.
Event Date: 
Sat, 10/14/2017 - 7:30am (EDT)
Conference Event Type: 

Newark

Thank you for attending the 2017 Patient and Family Conference in Newark, NJ.

Thank you for attending the 2017 Patient and Family Conference in Newark, NJ.
Event Date: 
Sat, 09/16/2017 - 8:00am (EDT)
Conference Event Type: 

Minneapolis

Thank you for attending the 2017 Minneapolis Patient and Family Conference.

Event Date: 
Sat, 07/22/2017 - 8:00am (EDT)
Conference Event Type: 

Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia

Author(s): 
Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir T. Fathi, Gail J. Roboz, Jessica K. Altman, Richard M. Stone, Daniel J. DeAngelo, Ross L. Levine, Ian W. Flinn, Hagop M. Kantarjian, Robert Collins, Manish R. Patel, Arthur E. Frankel, Anthony S
Primary Author: 
Eytan M. Stein
Journal Title: 
Blood
Original Publication Date: 
May 2017

Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ~12% of patients with

Bone Marrow Disease(s): 
Share with addtoany.com.